Teva Pharmaceutical Industries (NYSE:TEVA) CAO Sells $371,460.00 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Teva Pharmaceutical Industries Trading Up 0.2%

TEVA stock opened at $30.39 on Friday. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The company has a fifty day moving average price of $24.44 and a two-hundred day moving average price of $20.06. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $30.56. The stock has a market cap of $34.86 billion, a price-to-earnings ratio of 50.65, a price-to-earnings-growth ratio of 1.81 and a beta of 0.67.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TEVA. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Scotiabank initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price target for the company. Bank of America upped their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Barclays assumed coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 target price for the company. Finally, The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $31.63.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Goldman Sachs raised its price target on TEVA to $35 and reiterated a “buy” rating, signaling Wall Street conviction in upside versus the current level. Goldman Sachs price target raise
• Positive Sentiment: Additional analyst support: JPMorgan, BofA and Barclays have recently increased targets/ratings (JPMorgan to $35, BofA to $32, Barclays initiating overweight), which likely helped lift sentiment and buying interest. Analyst notes
• Positive Sentiment: Teva’s U.S. affiliate and Alvotech reached a settlement and license with Regeneron setting a U.S. launch window for AVT06 (a proposed biosimilar to Eylea) in Q4 2026 (or earlier under certain conditions) — this reduces launch uncertainty and creates a clearer commercialization timeline. Alvotech settlement
• Neutral Sentiment: Institutional activity is mixed but notable: several funds increased stakes (e.g., Hudson Bay Capital bought more), supporting the view that institutions are accumulating at current levels. Institutional trading
• Neutral Sentiment: Coverage pieces from Zacks and The Motley Fool highlight TEVA as a value/long-term holding — these narrative articles may attract retail interest but are less likely to move price materially on their own. Zacks coverage
• Negative Sentiment: Insider selling: CAO Amir Weiss sold 12,300 shares and Director Roberto Mignone sold 77,400 shares in mid-December at ~\$30.20–30.24 — sizable disclosed sales that may concern some investors about near-term insider conviction. Insider sales

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently modified their holdings of TEVA. Advisors Asset Management Inc. bought a new position in shares of Teva Pharmaceutical Industries in the second quarter worth $41,000. Cromwell Holdings LLC increased its holdings in Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the period. Sound Income Strategies LLC raised its position in shares of Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after buying an additional 2,824 shares in the last quarter. MAI Capital Management lifted its holdings in shares of Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after acquiring an additional 697 shares during the period. Finally, Rothschild Investment LLC boosted its position in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after acquiring an additional 1,348 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.